Aytu BioPharma AYTU 深 滬
等待開盤 11-04 09:30:00 美东时间
1.93
-0.010
-0.52%
華盛通- 最 高1.97
- 今 開1.94
- 成交量 9903股
- 最 低 1.93
- 昨 收 1.94
- 總市值 2097.56万
- 52周最高 3.065
- 市盈率 靜 --
- 換手率 0.09%
- 52周最低 1.89
- 委 比 77.68%
- 總股本 1086.82万
- 歷史最高 12920.00
- 量 比 0.28
- 振 幅 2.06%
- 歷史最低 0.95
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股前瞻 | 谷歌喊话Gemini 4超越OpenAI！美光财报“炸裂”却股价震荡，埃森哲绩后暴涨20%
油价重返100美元！美债“抛售潮”愈演愈烈；谷歌自信喊话Gemini 4超越OpenAI；美光财报炸裂却股价震荡，埃森哲绩后暴涨20%>>
10-01 20:11
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BNP Paribas raised the price target for Carmax Inc (NYSE:KMX) from $33 to $48. BNP Paribas analyst Chris Botti...
09-30 20:22
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14.5 to $15.
09-30 17:56
Aytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly sales of $16.106 million which beat the analyst consensus estimate of $12.276 million by 31.20 percent. This is a 6.42 percent increase over sales of $15.135 million the same period last year.
09-23 04:06
Aytu BioPharma Q4 2026 Earnings Preview
Aytu BioPharma (AYTU) is scheduled to announce Q4 earnings results on Monday, September 21st, after market close. The consensus EPS Estimate is -$0.35 (+88.1% Y/Y) and the consensus Revenue Estimate i...
09-22 05:35
美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.
06-11 17:44
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call
Aytu BioPharma (NASDAQ:AYTU) released third-quarter financial results and hoste...
05-14 05:39
Aytu BioPharma Q3 EPS $(0.53) Misses $(0.51) Estimate, Sales $12.411M Beat $12.053M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.51) by 3.92 percent. This is a 352.38 percent decrease over earnings of $0.21 per share from
05-14 04:07
